Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Zimmer Biomet Holdings Inc Stock Research

ZBH

110.76USD-1.70(-1.51%)Market Closed
Watchlist

Market Summary

USD110.76-1.70
Market Closed
-1.51%

ZBH Alerts

  • 5 major insider buys recently.
  • Big jump in Earnings (Y/Y)

ZBH Stock Price

ZBH RSI Chart

ZBH Valuation

Market Cap

23.1B

Price/Earnings (Trailing)

45.7

Price/Sales (Trailing)

3.21

EV/EBITDA

16.15

Price/Free Cashflow

21.08

ZBH Price/Sales (Trailing)

ZBH Profitability

EBT Margin

8.29%

Return on Equity

3.7%

Return on Assets

2.12%

Free Cashflow Yield

4.74%

ZBH Fundamentals

ZBH Revenue

Revenue (TTM)

7.2B

Revenue Y/Y

4.93%

Revenue Q/Q

2.11%

ZBH Earnings

Earnings (TTM)

505.6M

Earnings Y/Y

36.37%

Earnings Q/Q

-9.85%

Price Action

52 Week Range

102.60149.25
(Low)(High)

Last 7 days

-7.9%

Last 30 days

-5.8%

Last 90 days

-23.7%

Trailing 12 Months

5.9%

ZBH Financial Health

Current Ratio

1.89

Debt/Equity

0.44

Debt/Cashflow

0.26

ZBH Investor Care

Dividend Yield

0.87%

Dividend/Share (TTM)

0.96

Buy Backs (1Y)

0.48%

Diluted EPS (TTM)

2.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for ZBH

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-30
Kolli Sreelakshmi
bought
120,370
120
1,000
-
2023-08-28
HAGEMANN ROBERT
bought
232,960
116
2,000
-
2023-08-25
BERNARD BETSY J
bought
100,023
114
871
-
2023-08-25
MICHELSON MICHAEL W
bought
150,150
115
1,300
-
2023-08-23
HIGGINS ARTHUR J
bought
115,613
115
1,000
-
2023-07-01
VAN ZUILEN WILFRED
acquired
-
-
2,633
pres, europe, m. east & africa
2023-07-01
Upadhyay Suketu
sold (taxes)
-245,697
146
-1,677
exec. vp, cfo
2023-07-01
Upadhyay Suketu
acquired
-
-
3,768
exec. vp, cfo
2023-06-01
Stellato Paul A
sold (taxes)
-25,056
127
-197
vp, controller & cao
2023-06-01
Stellato Paul A
acquired
-
-
628
vp, controller & cao

1–10 of 50

Which funds bought or sold ZBH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-26
BROOKFIELD Corp /ON/
sold off
-100
-11,057,600
-
-%
2023-09-21
Jefferies Group LLC
new
-
810,263
810,263
0.01%
2023-09-21
Baystate Wealth Management LLC
unchanged
-
1,789
15,666
-%
2023-09-20
BARCLAYS PLC
added
89.02
36,139,000
68,115,000
0.04%
2023-09-12
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP
sold off
-100
-1,938,000
-
-%
2023-09-12
Farther Finance Advisors, LLC
added
67.14
23,974
51,106
0.01%
2023-09-07
ST GERMAIN D J CO INC
new
-
10,634,300
10,634,300
0.56%
2023-08-28
DT Investment Partners, LLC
unchanged
-
-4,002
80,685
0.01%
2023-08-25
EUBEL BRADY & SUTTMAN ASSET MANAGEMENT INC
added
0.58
3,068,000
26,046,000
3.59%
2023-08-24
Alberta Investment Management Corp
reduced
-79.96
-19,202,800
5,600,650
0.05%

1–10 of 46

Latest Funds Activity

Are funds buying ZBH calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ZBH
No. of Funds

Schedule 13G FIlings of Zimmer Biomet Holdings

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
price t rowe associates inc /md/
5.3%
11,200,109
SC 13G
Feb 09, 2023
vanguard group inc
11.46%
24,055,739
SC 13G/A
Jan 30, 2023
blackrock inc.
10.4%
21,803,709
SC 13G/A
Jan 24, 2023
blackrock inc.
10.4%
21,803,709
SC 13G/A
Apr 08, 2022
vanguard group inc
11.04%
23,102,761
SC 13G/A
Jan 28, 2022
jpmorgan chase & co
5.4%
11,340,168
SC 13G
Jan 28, 2022
blackrock inc.
10.4%
21,793,439
SC 13G/A
Apr 12, 2021
blackrock inc.
10.0%
20,926,542
SC 13G/A
Feb 11, 2021
massachusetts financial services co /ma/
4.8%
10,001,947
SC 13G/A
Feb 10, 2021
vanguard group inc
7.58%
15,703,785
SC 13G/A

Recent SEC filings of Zimmer Biomet Holdings

View All Filings
Date Filed Form Type Document
Sep 06, 2023
4
Insider Trading
Sep 06, 2023
4
Insider Trading
Sep 01, 2023
4
Insider Trading
Aug 30, 2023
4
Insider Trading
Aug 29, 2023
4
Insider Trading
Aug 29, 2023
4
Insider Trading
Aug 25, 2023
4
Insider Trading
Aug 22, 2023
8-K
Current Report
Aug 01, 2023
10-Q
Quarterly Report
Aug 01, 2023
8-K
Current Report

Peers (Alternatives to Zimmer Biomet Holdings)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
104.1B
31.6B
-3.89% -3.30%
28.69
3.3
1.57% -30.40%
102.4B
6.7B
-3.33% 56.36%
71.85
15.36
11.75% -0.66%
101.2B
19.5B
-4.23% 31.95%
37.36
5.2
10.36% 30.30%
71.3B
19.0B
-8.08% 14.20%
44.09
3.79
0.46% -5.24%
42.6B
5.7B
-7.79% -14.88%
30.67
7.53
5.64% -4.53%
MID-CAP
9.2B
937.8M
-4.69% 30.64%
316.65
9.84
16.30% 250.21%
7.3B
616.6M
-6.84% -23.46%
30.01
11.87
69.52% 343.68%
5.0B
1.1B
-7.21% -13.95%
23.85
4.57
12.63% 50.85%
2.8B
452.1M
-9.56% -23.21%
-28.09
6.17
24.99% 24.09%
1.4B
790.3M
-20.84% -55.28%
-6.03
1.71
3.21% -1604.53%
SMALL-CAP
955.9M
780.7M
-5.94% -5.33%
-26.55
1.22
4.68% -510.17%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%
610.4M
162.2M
26.12% -37.36%
-7.26
3.76
9.71% 12.37%
590.7M
162.9M
-24.99% -65.29%
-11.17
3.63
42.67% 12.82%

Zimmer Biomet Holdings News

InvestorsObserver
Is Zimmer Biomet Holdings Inc (ZBH) a Good Buy in the Healthcare Sector?.
InvestorsObserver,
11 hours ago
London South East
The Globe and Mail

Returns for ZBH

Cumulative Returns on ZBH

4%


10-Year Cumulative Returns

-1.1%


7-Year Cumulative Returns

-2.3%


5-Year Cumulative Returns

-5.2%


3-Year Cumulative Returns

Risks for ZBH

What is the probability of a big loss on ZBH?

70.4%


Probability that Zimmer Biomet Holdings stock will be more than 20% underwater in next one year

34.6%


Probability that Zimmer Biomet Holdings stock will be more than 30% underwater in next one year.

18.5%


Probability that Zimmer Biomet Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ZBH drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Zimmer Biomet Holdings was unfortunately bought at previous high price.

Drawdowns

Financials for Zimmer Biomet Holdings

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue1.2%7,1967,1086,9406,8926,9086,8896,8277,1357,3796,8427,0257,0657,0287,7917,9827,9287,8727,8917,9337,9307,907
  S&GA Expenses1.1%2,8242,7932,7622,8402,8692,8712,8432,4672,5732,5412,7132,6322,6692,8432,8103,4603,4223,3743,3793,2463,170
EBITDA-100.0%-1,3421,1651,1551,0501,1671,2771,5991,6851,2855466295489021,685------
EBITDA Margin-100.0%-0.19*0.17*0.17*0.15*0.15*0.16*0.21*0.22*0.18*0.08*0.09*0.08*0.12*0.21*------
Interest Expenses-7.4%-184-171-164-171-181-197-208-212-214-213-212-211-214-219-227-243-253-269-289-793-643
Earnings Before Taxes13.1%6665894043944083864999481,013613-105-206-27785.00880-249-280-202-271471444
EBT Margin-100.0%-0.08*0.06*0.06*0.04*0.04*0.05*0.10*0.11*0.06*-0.04*-0.03*-0.04*0.01*0.11*------
Net Income12.4%506450231278230218402819916568-138-15137.003771,132-90.20-359-307-3791,7531,690
Net Income Margin-100.0%-0.06*0.03*0.04*0.03*0.03*0.05*0.11*0.12*0.08*-0.02*-0.02*0.01*0.05*0.14*------
Free Cashflow-100.0%-1,1501,1681,2761,2941,4161,3561,4281,3998951,0871,0611,2301,5441,379------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets0.2%21,29421,24421,06621,33321,45321,61823,45624,00924,22324,02724,41824,02623,64825,51324,63924,31524,20624,28924,12725,38225,491
  Current Assets-0.5%4,3884,4124,4274,5344,4634,5174,8855,3125,3575,0005,0835,1534,7076,3714,7244,4024,3914,4994,4274,5134,475
    Cash Equivalents-3.1%3203303765453864363789201,0427247759677132,434618513403587543525481
  Inventory1.5%2,2762,2412,1472,1292,1232,1322,1482,5172,5332,5122,1742,4922,4972,4632,3852,3622,3452,3102,2572,2202,159
  Net PPE3.6%1,9751,9061,8731,8021,7971,8261,8372,0082,0052,0221,8642,0432,0572,0662,0772,0552,0362,0142,0152,0021,987
  Goodwill0.1%8,7448,7358,5808,7998,8698,8968,9199,2129,2489,2338,9839,0398,9828,9519,1979,5459,5949,5709,59410,58410,596
Liabilities-1.9%8,9169,0869,0399,0829,3289,59610,79011,29411,64011,57712,21812,14712,00413,63012,24612,23012,54412,75012,85113,15913,447
  Current Liabilities-4.4%2,2342,3362,3582,2962,4642,6743,4682,9392,9292,0892,5572,2662,1613,7803,4423,7743,6782,2552,4212,3911,854
    LT Debt, Current-11.1%5205855446598521,0151,6051,0461,0503005004504501,9501,5002,0002,000500525600100
    LT Debt, Non Current-0.3%5,1895,2055,1525,0555,1725,2865,4646,4586,8037,5397,6277,8407,7597,7246,7216,3466,7198,3118,4148,5979,413
Shareholder's Equity1.8%12,37212,15812,02012,24512,12512,02112,66612,71412,58312,45012,19911,87811,64411,88312,39312,08611,66211,53911,27612,22312,044
  Retained Earnings1.6%9,9029,7429,5599,7409,6079,50310,29210,42610,33110,23810,0879,8039,6109,86610,42710,1559,7739,6889,49110,44110,328
  Additional Paid-In Capital0.8%9,7669,6929,5049,4649,4199,3869,3159,2959,2499,1999,1229,0739,0148,9848,9208,8678,7778,7488,6868,6628,597
Shares Outstanding-0.4%209209-210210209-209209208-212212212-211210210-209208
Minority Interest2.9%7.007.007.006.006.006.006.006.005.005.005.006.003.004.005.004.003.005.005.006.001.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations0.2%1,3511,3481,3561,4501,4231,4971,4041,3631,3208481,0761,0071,2031,5571,3901,5421,4481,5411,7471,7711,750
  Share Based Compensation5.9%11310710593.0084.0079.0076.0073.0078.0077.0074.0078.0076.0073.0077.0082.0080.0072.0066.0059.0052.00
Cashflow From Investing0.0%-590-590-522-533-560-416-443-585-564-551-564-351-423-660-644-673-649-420-416-462-444
Cashflow From Financing4.3%-823-860-775-1,118-1,350-1,232-1,306-934-551-2,108-420-315-571850-777-872-872-2,279-1,302-1,259-1,282
  Dividend Payments0%201201201201201201200200199199199198198197197196196196195195195
  Buy Backs-47.3%5641,070126------------------

ZBH Income Statement

2023-06-30
Condensed Consolidated Statements of Earnings (unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Net Sales$ 1,869.6$ 1,781.8$ 3,700.6$ 3,445.0
Type of Revenue [Extensible List]us-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMember
Cost of products sold, excluding intangible asset amortization$ 525.5$ 511.0$ 1,026.3$ 1,011.0
Type of Cost, Good or Service [Extensible List]us-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMember
Intangible asset amortization$ 138.2$ 133.0$ 271.6$ 263.8
Research and development118.199.4228.5196.3
Selling, general and administrative725.8695.21,441.81,379.7
Intangible asset impairment 3.0 3.0
Restructuring and other cost reduction initiatives24.457.066.3100.9
Quality remediation 7.8 14.3
Acquisition, integration, divestiture and related7.9(5.5)9.1(3.3)
Operating expenses1,539.91,500.93,043.62,965.7
Operating Profit329.6280.9656.9479.3
Other (expense) income, net(1.2)(42.6)6.5(98.7)
Interest expense, net(51.6)(38.8)(99.8)(79.9)
Earnings from continuing operations before income taxes276.8199.5563.6300.7
Provision for income taxes from continuing operations66.945.5121.073.5
Net Earnings from continuing operations209.9154.0442.6227.2
Less: Net earnings attributable to noncontrolling interest0.20.30.50.5
Net Earnings from Continuing Operations of Zimmer Biomet Holdings, Inc.209.6153.7442.1226.7
Loss from discontinued operations, net of taxes   (58.8)
Net Earnings of Zimmer Biomet Holdings, Inc.$ 209.6$ 153.7$ 442.1$ 167.9
Earnings Per Common Share - Basic    
Earnings from continuing operations$ 1.00$ 0.73$ 2.12$ 1.08
Loss from discontinued operations   (0.28)
Net Earnings Per Common Share - Basic1.000.732.120.80
Earnings Per Common Share - Diluted    
Earnings from continuing operations1.000.732.101.08
Loss from discontinued operations   (0.28)
Net Earnings Per Common Share - Diluted$ 1.00$ 0.73$ 2.10$ 0.80
Weighted Average Common Shares Outstanding    
Basic208.6209.6209.0209.4
Diluted209.9210.3210.1210.2

ZBH Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Current Assets:  
Cash and cash equivalents$ 319.8$ 375.7
Accounts receivable, less allowance for credit losses1,367.31,381.5
Inventories2,275.82,147.2
Prepaid expenses and other current assets425.1522.9
Total Current Assets4,387.94,427.3
Property, plant and equipment, net1,975.01,872.5
Goodwill8,743.78,580.2
Intangible assets, net5,027.75,063.8
Other assets1,160.01,122.2
Total Assets21,294.321,066.0
Current Liabilities:  
Accounts payable354.6354.1
Income taxes payable81.638.5
Other current liabilities1,277.61,421.3
Current portion of long-term debt520.0544.3
Total Current Liabilities2,233.72,358.2
Deferred income taxes, net474.9474.8
Long-term income tax payable375.7421.2
Other long-term liabilities642.0632.6
Long-term debt5,189.45,152.2
Total Liabilities8,915.89,039.0
Commitments and Contingencies (Note 16)
Stockholders' Equity:  
Common stock, $0.01 par value, one billion shares authorized, 315.8 million shares as of June 30, 2023 (313.8 million as of December 31, 2022) issued3.23.1
Paid-in capital9,766.09,504.4
Retained earnings9,902.39,559.3
Accumulated other comprehensive loss(177.8)(179.3)
Treasury stock, 107.0 million shares as of June 30, 2023 (104.8 million as of December 31, 2022)(7,122.2)(6,867.2)
Total Zimmer Biomet Holdings, Inc. stockholders' equity12,371.512,020.3
Noncontrolling interest7.16.7
Total Stockholders' Equity12,378.612,027.0
Total Liabilities and Stockholders' Equity$ 21,294.3$ 21,066.0
Bryan C. Hanson
19500
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.